Morning Overview on MSN
A phase 1/2 trial just reported exceptional disease control on pancreatic cancer using daraxonrasib — a targeted drug aimed at the mutation doctors once called untreat…
For more than three decades, oncologists have watched the same story play out with pancreatic cancer. A patient’s tumor is ...
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced updated data from the ...
EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours Data presented at 2026 ASCO® Annual Meeting show ODM-212 was ...
Updateddata across two dose levels of 200 mW/cm and 400 mW/cmin LA-PDAC trialshow71% (5/7) patients resected following VTP with a consistent and well-tolerated safety profile- ...
Fred Hutchinson Cancer Center leads the way when it comes to offering eligible patients alternative options when conventional therapies no longer work. With more than two dozen phase 1 clinical trials ...
Huntsman Cancer Institute at the University of Utah stands at the forefront of innovative cancer research and treatment. Phase 1 clinical trials are key to finding better ways to treat cancer safely ...
A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM). This is an ASCO Meeting ...
Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results